Ontology highlight
ABSTRACT:
SUBMITTER: Koopmeiners JS
PROVIDER: S-EPMC5581285 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature

Koopmeiners Joseph S JS Wey Andrew A
Journal of biopharmaceutical statistics 20170325 6
The primary object of a Phase I clinical trial is to determine the maximum tolerated dose (MTD). Typically, the MTD is identified using a dose-escalation study, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher dose levels until the MTD is identified. The continual reassessment method (CRM) is a popular model-based dose-escalation design, which utilizes a formal model for the relationship between dose and toxicity to guide dos ...[more]